As a tumor antigen, CD73 has been shown to be a viable target, highly expressed in lung adenocarcinoma, with increased expression in mutated EGFR+ lung adenocarcinoma patients Velez and Burns, 2019; Streicher et al., 2017. The gene discussed is NT5E; the disease is lung adenocarcinoma.